Publications

Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GNicolò, Pannellini T, Socciarelli F, Van Emmenis L, Rodrigues S, Fidalgo-Ribeiro C et al..  2024.  Distinct mesenchymal cell states mediate prostate cancer progression.. Nat Commun. 15(1):363.

Van Emmenis L, Ku S-Y, Gayvert K, Branch JR, Brady NJ, Basu S, Russell M, Cyrta J, Vosoughi A, Sailer V et al..  2023.  The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer.. Cancer Res Commun. 3(8):1447-1459.

Germanos AA, Arora S, Zheng Y, Goddard ET, Coleman IM, Ku AT, Wilkinson S, Song H, Brady NJ, Amezquita RA et al..  2022.  Defining cellular population dynamics at single-cell resolution during prostate cancer progression.. Elife. 11

Brady NJ, Barbieri CE.  2022.  JAK inhibition shows two faces in prostate cancer.. Nat Cancer. 3(9):1021-1023.

Labrecque MP, Brown LG, Coleman IM, Lakely B, Brady NJ, Lee JK, Nguyen HM, Li D, Hanratty B, Haffner MC et al..  2021.  RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.. Cancer Res. 81(18):4736-4750.

Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, Pakula H, Carelli R, Khani F, Bakht M et al..  2021.  Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.. Nat Commun. 12(1):3372.

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.